Guanine Quadruplex Binding Compounds with Selective DNA Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for targeting guanine quadruplexes have limitations, particularly in their affinity for duplex DNA and stability, which hinders their effectiveness in therapeutic applications such as cancer treatment and viral regulation.
Innovation Solution
Development of compounds with a specific chemical formula that selectively bind to guanine quadruplexes, including those at telomeres and gene promoters, with low affinity for duplex DNA, thereby inhibiting telomerase activity and oncogene expression, and potentially treating various diseases like cancer and HIV.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current strategies for targeting guanine quadruplexes are used, then some binding activity is achieved, but affinity for duplex DNA is too high and stability is insufficient
Solution Approach 1:
The compound features a planar aromatic core structure specifically optimized for G4 binding, with local functional groups positioned to interact with G4 grooves or loops. This localized structural design enables selective stabilization of G4 structures while minimizing non-specific binding to duplex DNA, thereby improving binding stability without increasing harmful duplex affinity.
Solution Approach 2:
The patent optimizes specific molecular parameters including the size and geometry of the planar aromatic platform, the nature and position of substituent groups, and the overall molecular shape to achieve optimal G4 binding. By carefully tuning these parameters, the compound achieves high stability for G4 binding while maintaining low affinity for duplex DNA, resolving the contradiction between reliable binding and selective targeting.
2Productivity
If compounds are designed to strongly bind guanine quadruplexes, then therapeutic effectiveness improves, but selectivity against duplex DNA becomes challenging
Solution Approach 1:
The compound employs an asymmetric planar aromatic structure with non-uniform distribution of functional groups around the core. This asymmetric design allows the molecule to fit specifically into the asymmetric architecture of G4 structures, achieving strong binding and high therapeutic effectiveness. Simultaneously, the asymmetric geometry does not match the symmetric structure of duplex DNA, providing inherent selectivity and preventing off-target binding.
Solution Approach 2:
The patent utilizes the two-dimensional planar aromatic platform to achieve binding through stacking interactions with G4 tetrads, while extending functionality into the third dimension through vertical stacking of multiple aromatic units or through side-chain interactions with G4 loops and ridges. This multi-dimensional binding approach enhances therapeutic effectiveness through strong stabilization while the specific geometric requirements in each dimension provide selectivity against duplex DNA.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate strong stabilization of guanine quadruplexes and selective binding, inhibiting cell growth in cancer cell lines and showing potential in treating a range of diseases by targeting guanine quadruplexes without interfering with duplex DNA.
Implementation Method 1
compounds that bind guanine quadruplexes... The compounds demonstrate strong stabilization of guanine quadruplexes and selective binding
Data Source
AI summary
Compounds are described and characterized that bind guanine quadruplexes of DNA or RNA. Binding data and inhibition of growth data of five cancer cell lines are presented.